| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3923511 | European Urology | 2006 | 9 Pages |
Abstract
Atrasentan provides QOL benefits relevant to HRPC. The quality-adjusted analyses applied in the atrasentan studies have begun to lay the foundation for interpreting clinical endpoints in conjunction with QOL. These analyses will facilitate better QOL comparisons within studies and across trials. Further evaluation of atrasentan in HRPC is warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
David Cella, Daniel P. Petrylak, Mayer Fishman, Chris Teigland, Jay Young, Parvez Mulani,